MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
about
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisLipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients.Association between polymorphisms in tumor suppressor genes and oncogenes and risk of hepatocellular carcinoma: a case-control study in an HCC epidemic area within the Han Chinese population.Association between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population.Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals.The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.MDM2 oncogene, E3 ubiquitin protein ligase T309G polymorphism and risk of oesophageal or gastric cancer: meta-analysis of 15 studies.The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
P2860
Q30840070-00840E87-6DE6-4E6E-AEAD-672FB059E7D4Q35220109-9314DCAB-7848-4DB7-851E-04105E5A64DDQ35440600-6D0B0E82-EC03-49D0-8E97-A2849EE3200DQ36046580-FB1A90B6-2FAC-4034-9BB5-7D62D6B7EE45Q36109482-9C941E41-37C2-428A-8EB9-39F3102FB706Q36664052-75062F0E-1B2E-42C4-9C2F-5336C9CBD0BDQ36956179-0C792425-4C5C-490C-A6D9-EA714551FD99Q38323624-0CFB4FB9-BE70-4C00-B189-FA2F671081DCQ38396084-F189E289-FCA4-4F33-B748-E6BA9717B734Q45228677-9F377FF2-5F9D-4C28-8648-043E367E95C2Q47799677-818C6B69-B8CE-4AA9-999A-F4876C190E01Q50864357-9E354127-CCD0-4A84-8324-36451CFA5442
P2860
MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@en
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@nl
type
label
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@en
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@nl
prefLabel
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@en
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@nl
P2093
P2860
P356
P1476
MDM2 promoter SNP309 is associ ...... in Chinese patients with CLL.
@en
P2093
Cheng Fang
Dan-Xia Zhu
Dong-Mei Wang
Hua-Jie Dong
Hua-Yuan Zhu
Jian-Yong Li
Kou-Rong Miao
P2860
P304
P356
10.1002/IJC.26222
P577
2011-08-09T00:00:00Z